A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.
Also called NCT06897475
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 200 participants
- Sponsor
- Registry
-
NCT06897475 -
2024-520328-27-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Canada, Germany, Poland, Puerto Rico, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT06897475. Randomized; double masking; primary purpose treatment. Start 2025-03-28 (actual); primary completion 2027-05 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- LY3457263
- Intervention (Drug)
- Placebo
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct06897475- Content hash
1c48b51622f5a7e80c1646f285a1fe7691e22062a4401dfa48950d6923e840c1